Organ Preservation Solution Market Report 2026

The organ preservation solution market size has grown strongly in recent years. It will grow from $0.31 billion in 2025 to $0.33 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to growth of organ transplantation procedures, expansion of transplant infrastructure, increasing availability of preservation solutions, adoption of cold storage techniques, advancements in medical preservation chemistry.

The organ preservation solution market size is expected to see strong growth in the next few years. It will grow to $0.43 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing organ transplant demand, rising adoption of advanced preservation technologies, expansion of machine perfusion systems, growing focus on transplant success rates, innovation in organ protection formulations. Major trends in the forecast period include advancements in ischemia-reperfusion injury mitigation, rising adoption of machine perfusion techniques, growing use of multi-organ preservation solutions, expansion of transplant storage durations, enhanced focus on organ viability.

The increase in healthcare spending is driving the growth of the organ preservation solution market. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. Organ preservation solutions are critical in optimizing the success of organ transplantation procedures, as they preserve organs during transportation and storage to ensure viability. Investment in these solutions contributes to improved transplant outcomes, reducing complications and associated healthcare costs. For instance, in November 2023, according to the Canadian Institute for Health Information, total health spending in Canada was projected to reach $344 billion, or $8,740 per person. This represents a 2.8% increase compared to the 1.5% growth in 2022, indicating a notable rebound in healthcare investment. Therefore, the increase in healthcare spending is propelling the growth of the organ preservation solution market going forward.

Product innovation is a significant trend gaining traction in the organ preservation solution market. Leading companies in this sector are concentrating on developing cutting-edge products to enhance their position and secure a competitive edge. For example, in June 2024, Paragonix Technologies, a US-based firm specializing in organ preservation technology, introduced the PancreasPak Organ Preservation System. This device is the first to receive FDA clearance specifically designed to protect and monitor donor pancreases during transportation, underscoring its crucial role in organ transplantation. The system creates a controlled environment that maintains the pancreas at an optimal thermal range of 4-8°C, which is vital for preserving the organ's viability and functionality during transport, which can last up to 21 hours. The PancreasPak is also equipped with digital monitoring capabilities that continuously track the temperature and surrounding conditions of the pancreas. This real-time data facilitates immediate action in response to any deviations from optimal conditions, thereby enhancing organ preservation.

In September 2024, Getinge, a Sweden-based medical technology firm, acquired Paragonix Technologies for $253 million. This acquisition enables Getinge to enter the fast-growing organ preservation and transportation market, which is witnessing substantial growth driven by rising transplant volumes and technological advancements. Paragonix Technologies is a US-based biotechnology company specializing in organ preservation solutions.

Major companies operating in the organ preservation solution market are Bridge to Life, XVIVO Perfusion, Organ Recovery Systems, Dr. Franz Köhler Chemie, BioLife Solutions, Essential Pharmaceuticals, Preservation Solutions, KPS Life, Hibernicor, Advanced Organ Biosciences, Paragonix Technologies, TransMedics, OrganOx, Organ Assist, XVIVO Lung Perfusion, Cell and Tissue Systems, Sustained Medical, Organ Preservation Alliance, Lifeline Scientific, Arthrex.

North America was the largest region in the organ preservation solution market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the organ preservation solution market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the organ preservation solution market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The organ preservation solution market consists of sales of the histidine-tryptophan-ketoglutarate solution and hypertonic citrate adenine solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.